Markets:

Overview

News

Currencies

International

Treasuries

Novartis AG Common Stock (NY:NVS)

141.54 +0.08 (+0.06%)

Official Closing Price Updated: 7:00 PM EST, Jan 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2

...

11 12 13 14 15 16 17 18 19

...

53 54 Next >

Is NYSE:NVS a Good Fit for Dividend Investing? ↗

July 12, 2024

Is NOVARTIS AG-SPONSORED ADR (NYSE:NVS) suited for dividend investing?

Via Chartmill

The 3 Most Undervalued Pharma Stocks to Buy in July 2024 ↗

July 12, 2024

Pharma stocks can be great investments during times of growth and recession, and are made even better if the stock is undervalued.

Via InvestorPlace

Topics Economy

Novartis Stock Generating Improved Relative Strength ↗

July 08, 2024

Top and bottom line growth moved higher in Novartis' most recent quarter. EPS rose 17% to $1.80. Revenue increased 10% to $12.1 billion.

Via Investor's Business Daily

Ozempic Maker Novo Nordisk Reprimanded by UK Regulators for Payment Disclosure Failures ↗

July 05, 2024

UK regulators reprimand Novo Nordisk for failing to disclose nearly $10 million in fees and expenses. The PMCPA cites breaches in financial categorization and highlights similar issues with Novartis...

Via Benzinga

What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients ↗

July 05, 2024

A number of companies are working on new drugs for high lipids, including cholesterol and triglycerides.

Via Investor's Business Daily

Exploring NYSE:NVS's dividend characteristics. ↗

June 21, 2024

Why NOVARTIS AG-SPONSORED ADR (NYSE:NVS) qualifies as a good dividend investing stock.

Via Chartmill

Balancing Dividends and Fundamentals: The Case of NYSE:NVS. ↗

May 30, 2024

Is NOVARTIS AG-SPONSORED ADR (NYSE:NVS) suited for dividend investing?

Via Chartmill

Upcoming Stock Spinoffs: Should You Pounce or Pass? ↗

July 04, 2024

Stock spinoffs are a unique opportunity to pick up unloved, unwanted businesses but patience is often needed before buying in.

Via InvestorPlace

Mississippi Judge Upholds State Law Mandating Drug Discounts for Low-Income Patients ↗

July 02, 2024

A Mississippi judge upheld a state law requiring drugmakers to offer discounts on medications through third-party pharmacies for low-income populations, rejecting lawsuits from PhRMA and Novartis.

Via Benzinga

Topics Lawsuit

Superlab Suisse opens state-of-the-art facility in Basel, fostering new spaces for scientific breakthroughs

June 25, 2024

With this new facility, Superlab Suisse becomes the largest private lab space in Switzerland.

Via News Direct

Novartis Stock Just Below Innovative Drugmaker's All-Time High; Gets Key Rating Upgrade ↗

June 25, 2024

Novartis stock is in a buy range after moving past a 103.55 entry in a cup with handle. The buy range extends to 5% above the initial entry.

Via Investor's Business Daily

Nestle Carefully Targets Weight-Loss Drug Users with New Food Line ↗

June 21, 2024

Nestle's new Vital Pursuit brand targets individuals on weight-loss drugs without mentioning medications on packaging, addressing regulatory concerns and focusing on marketing through social media.

Via Benzinga

German Drug Developer Evotec Seeks Adviser Input As Takeover Concerns Mount ↗

June 20, 2024

Evotec consults defense advisers following a significant share price decline, raising concerns about a potential takeover.

Via Benzinga

What's Going On With Neurological Disease Focused Trevena On Thursday? ↗

June 20, 2024

Trevena shares dropped 33.7% to $0.23 with a session volume of 23.65 million. Notably, TRV045 did not cause S1P1R desensitization or protein reduction, unlike fingolimod.

Via Benzinga

7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline ↗

June 17, 2024

With biotech stocks enjoying a permanently relevant narrative, investors should focus on these compelling opportunities.

Via InvestorPlace

3 Crazy Good Stocks to Buy With $500 Right Now ↗

June 12, 2024

For investors with only a little money to spare, these three supercharged stocks represent an outrageous opportunity for future growth.

Via InvestorPlace

Italy Probes European Pharma Giants Novartis, Roche Over Eye Drug Competition Allegations ↗

June 06, 2024

Italy's antitrust authority is investigating Novartis and Roche's Genentech for allegedly delaying the Italian market launch of Byooviz, a Samsung Bioepis biosimilar of Lucentis.

Via Benzinga

Leigh Burgess, CEO & Founder Bold Industries Group, Announces Pre-Sale of New Book: Be BOLD Today

June 04, 2024

Via Get News

The 3 Most Undervalued Healthcare Stocks to Buy in June 2024 ↗

June 04, 2024

Seeking discounts in relevant places makes sense and there are few arenas more compelling than undervalued healthcare stocks.

Via InvestorPlace

Novartis Sues to Block Maryland's New Drug Discount Law ↗

May 31, 2024

Novartis has filed a lawsuit to block a Maryland law requiring drugmakers to offer discounts on drugs through third-party pharmacies contracting with hospitals and clinics.

Via Benzinga

Topics Lawsuit

Novartis' Oral Drug For Chronic Skin Disease Candidate Shows Efficacy, Long-term Safety ↗

May 31, 2024

Novartis reveals Phase 3 data confirming remibrutinib's long-term efficacy and safety for chronic spontaneous urticaria, showing significant symptom improvement and a favorable safety profile up to...

Via Benzinga

After UnitedHealth Cyberattack, Drug Distributor Cencora Notifies Americans' Health Information Stolen In Data Breach In February ↗

May 24, 2024

Cencora reports a cyberattack exposing sensitive medical information, including patient names, addresses, birth dates, diagnoses, and medications.

Via Benzinga

Topics Data Breach

Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game ↗

May 16, 2024

On Sunday, Pfizer (NYSE: PFE) and AstraZeneca Plc (NASDAQ: AZN) were among the pharmaceutical companies who announced they will be investing a total of nearly $1 billion in their operations in France,...

Via Benzinga

7 Pharma Stocks Harnessing AI Brainpower for Big Breakthroughs ↗

May 16, 2024

AI continues to impact pharma stocks to buy in a major way, with these shares particularly well positioned as things heat up.

Via InvestorPlace

Topics Artificial Intelligence

Patent Peril: 3 Stocks at Risk From the FTC’s Drug Crusade ↗

May 16, 2024

The FTC is putting these three drug stocks at risk by trying to strip their therapies of protection from generics.

Via InvestorPlace

Topics Intellectual Property

3 Magnificent Stocks That Are Passive Income Machines ↗

May 14, 2024

These three companies have track records that should please investors.

Via The Motley Fool

The 3 Best Mutual Funds to Buy in May 2024 ↗

May 11, 2024

Consider the best mutual funds to buy for high returns and low fees. They each have unique strategies meant to maximize returns on capital.

Via InvestorPlace

MacroGenics Gets Downgraded Following Disappointing Prostate Cancer Trial Results: 'We Were Surprised By Reported Deaths' ↗

May 10, 2024

Despite MacroGenics' clinical activity, unexpected adverse events raise concerns. Analysts adjust ratings and price targets.

Via Benzinga

3 Biotech Stocks to Sell in May Before They Crash & Burn ↗

May 10, 2024

Discover essential insights on biotech stocks to sell in May to navigate market volatility and safeguard your investment portfolio.

Via InvestorPlace

Google DeepMind Develops Latest AI Model To Aid Scientists In Fighting Disease ↗

May 08, 2024

Google DeepMind reveals its AlphaFold 3, which specializes in molecular predictions for proteins, DNA, RNA, and drug molecules.

Via Benzinga

Topics Artificial Intelligence

< Previous 1 2

...

11 12 13 14 15 16 17 18 19

...

53 54 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Novartis AG Common Stock (NY:NVS)

All News about Novartis AG Common Stock

Starting at $3.75/week.

Subscribe Today